Antimicrobial therapy during cancer treatment: Beyond antibacterial effects

S. Ghanem; C.J. Kim; D. Dutta; M. Salifu; S.H. Lim

doi:10.1111/joim.13238

journal article Feb 12, 2021

Antimicrobial therapy during cancer treatment: Beyond antibacterial effects

S. Ghanem C.J. Kim D. Dutta

M. Salifu S.H. Lim

Journal of Internal Medicine Vol. 290 No. 1 pp. 40-56 · Wiley

View at Publisher Save 10.1111/joim.13238

Abstract

AbstractCancer treatment options have evolved to include immunotherapy and targeted therapy, in addition to traditional chemoradiation. Chemoradiation places the patient at a higher risk of infection through a myelosuppressive effect. High clinical suspicion and early use of antimicrobials play a major role in decreasing any associated morbidity and mortality. This has led to a widespread use of antimicrobials in cancer patients. Antimicrobial use, however, does not come without its perils. Dysbiosis caused by antimicrobial use affects responses to chemotherapeutic agents and is prognostic in the development and severity of certain cancer treatment‐related complications such as graft‐versus‐host disease and Clostridioides difficile infections. Studies have also demonstrated that an intact gut microbiota is essential in the anticancer immune response. Antimicrobial use can therefore modulate responses and outcomes with immunotherapy targeting immune checkpoints. In this review, we highlight the perils associated with antimicrobial use during cancer therapy and the importance of a more judicious approach. We discuss the nature of the pathologic changes in the gut microbiota resulting from antimicrobial use. We explore the effect these changes have on responses and outcomes to different cancer treatment modalities including chemotherapy and immunotherapy, as well as potential adverse clinical consequences in the setting of stem cell transplant.

Topics

No keywords indexed for this article. Browse by subject →

References

104

[1]

10.1016/s0959-8049(01)00461-0

[2]

10.1200/jop.18.00366

[3]

10.1186/s40364-020-00211-6

[4]

Structure, function and diversity of the healthy human microbiome

Nature 10.1038/nature11234

[5]

The Pervasive Effects of an Antibiotic on the Human Gut Microbiota, as Revealed by Deep 16S rRNA Sequencing

Les Dethlefsen, Sue Huse, Mitchell L Sogin et al.

PLOS Biology 10.1371/journal.pbio.0060280

[6]

Long-term ecological impacts of antibiotic administration on the human intestinal microbiota

Cecilia Jernberg, Sonja Löfmark, Charlotta Edlund et al.

The ISME Journal 10.1038/ismej.2007.3

[7]

10.1371/journal.pone.0126712

[8]

10.1016/j.cmi.2014.11.016

[9]

10.1016/j.humic.2018.11.004

[10]

10.1016/j.lfs.2018.06.030

[11]

10.1159/000443360

[12]

10.1016/j.jinf.2019.10.008

[13]

10.1093/jac/dkw383

[14]

10.3748/wjg.v23.i25.4491

[15]

10.1016/j.anaerobe.2018.04.012

[16]

Butyrate Enhances Intestinal Epithelial Barrier Function via Up-Regulation of Tight Junction Protein Claudin-1 Transcription

Hong-bo Wang, Peng-Yuan Wang, Xin Wang et al.

Digestive Diseases and Sciences 10.1007/s10620-012-2259-4

[17]

10.1126/science.aat9076

[18]

10.1016/j.jnutbio.2010.07.009

[19]

10.1016/j.nutres.2008.02.012

[20]

10.1080/19490976.2015.1062959

[21]

Same Exposure but Two Radically Different Responses to Antibiotics: Resilience of the Salivary Microbiome versus Long-Term Microbial Shifts in Feces

Egija Zaura, Bernd W. Brandt, M. Joost Teixeira de Mattos et al.

mBio 10.1128/mbio.01693-15

[22]

10.1016/j.cell.2015.10.048

[23]

NLRP6 Inflammasome Orchestrates the Colonic Host-Microbial Interface by Regulating Goblet Cell Mucus Secretion

Marta Wlodarska, Christoph A. Thaiss, Roni Nowarski et al.

Cell 10.1016/j.cell.2014.01.026

[24]

NLRP6 Inflammasome Regulates Colonic Microbial Ecology and Risk for Colitis

Eran Elinav, Till Strowig, Andrew L. Kau et al.

Cell 10.1016/j.cell.2011.04.022

[25]

10.1146/annurev.micro.091208.073341

[26]

10.1371/journal.pone.0032094

[27]

10.1038/nature14139

[28]

Immunoglobulin A Coating Identifies Colitogenic Bacteria in Inflammatory Bowel Disease

Noah W. Palm, Marcel R. de Zoete, Thomas W. Cullen et al.

Cell 10.1016/j.cell.2014.08.006

[29]

10.1038/ismej.2015.114

[30]

10.1038/nature07008

[31]

10.1073/pnas.0909122107

[32]

10.1126/science.1206095

[33]

10.1038/s42255-018-0017-4

[34]

Xenobiotics Shape the Physiology and Gene Expression of the Active Human Gut Microbiome

Corinne Ferrier Maurice, Henry Joseph Haiser, Peter James Turnbaugh

Cell 10.1016/j.cell.2012.10.052

[35]

10.1002/ajh.25722

[36]

10.3389/fcimb.2019.00044

[37]

Griffin MO "Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. American Journal of Physiology‐Cell" Physiology (2010)

[38]

10.2174/1874210601408010109

[39]

10.1073/pnas.93.24.14014

[40]

10.1128/aac.40.4.934

[41]

10.1128/aac.47.11.3630-3633.2003

[42]

10.1016/s0014-2999(01)01321-8

[43]

10.1128/cmr.00078-09

[44]

Azithromycin: Mechanisms of action and their relevance for clinical applications

Michael J. Parnham, Vesna Erakovic Haber, Evangelos J. Giamarellos-Bourboulis et al.

Pharmacology & Therapeutics 10.1016/j.pharmthera.2014.03.003

[45]

10.1016/j.intimp.2010.12.010

[46]

10.1038/srep12016

[47]

Microbiota-Generated Metabolites Promote Metabolic Benefits via Gut-Brain Neural Circuits

Filipe De Vadder, Petia Kovatcheva-Datchary, Daisy Goncalves et al.

Cell 10.1016/j.cell.2013.12.016

[48]

10.1016/j.cmet.2015.09.028

[49]

10.1016/j.cell.2018.09.055

[50]

10.1126/science.1240527

Showing 50 of 104 references

Metrics

16

Citations

104

References

Details

Published: Feb 12, 2021
Vol/Issue: 290(1)
Pages: 40-56
License: View

Authors

S

S. Ghanem